Rebalix
Logo VanguardVanguard · sheet of 5 September 2026
ETF sheet · official issuer and register data

Vanguard ESG Developed Europe All Cap UCITS ETF (EUR) Distributing

V3EL · IE000NRGX9M3 · EUR · domicile Ireland
Equity · Europe · All sizesSFDR art. 8
Index tracked: FTSE Developed Europe All Cap Choice Index
TER
0.12%+ trans. 0.08%
Fund size
160 m EUR
Tracking difference
+0.32%3-year avg
🇮🇹 tax rate
26.00%equity
Replication
Physical (full replication)
Income
Distributingquarterly
Launch 16 Aug 2022 · costs from the KID as of 2 Sept 2026 · 1,012 securities held · 11 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
The Fund employs a passive management – or indexing – investment approach, through physical acquisition of securities, and seeks to track the performance of the FTSE Developed Europe All Cap Choice Index (the “Index”). The Fund attempts to track the performance of the Index by investing all, or substantially all, of its assets in the stocks that make up the Index in approximately the same proportion as the Index. Where not practicable to fully replicate, the Fund will use a sampling process. The Index is a market-capitalisation-weighted index composed of…

Performance since series start (in euro) — base 100

30 Sept 202231 Jul 2026 · dividends reinvested where declared by the issuer
2023202420252026180100180
High 180 (31 Jul 2026) · low 100 (30 Sept 2022) · last 180. Past performance is not indicative of future results.

Returns in euro

1 year+19.9%
3 years+44.5%
5 yearsseries too young
10 yearsseries too young
Since series start+79.8%

Risk · 1 / 3 / 5 years

Volatility (ann.)12.97%12.83%
Max drawdown−10.84%−16.61%
Sharpe1.060.63
Sortino1.620.88
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · V3EL · IE000NRGX9M31
RebalixV3EL · IE000NRGX9M3 · sheet of 5 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+17.39%+17.02%+0.37%
2024+9.56%+9.30%+0.26%
2023+16.62%+16.30%+0.33%

Distributions · per share, in EUR

Frequency: quarterly · last 12 months: 0.1782 EUR (2.52% of NAV) · last ex-date 18 Jun 2026
YearPaymentsTotal (EUR)Dividend yield
202620.1406
202540.1742+3.06%
202440.1612+3.01%
202340.1415+3.00%
202220.0177
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.

Holdings

Portfolio as declared by the issuer · 31 Jul 2026 · 1,012 securities · top-10 weight = 24.2%
Top holdingsWeight
ASML Holding NV5.6%
Roche Holding AG2.7%
Novartis AG2.6%
Nestle SA2.3%
AstraZeneca PLC2.2%
Siemens AG2.1%
Banco Santander SA1.8%
Euro1.7%
Allianz SE1.7%
SAP SE1.6%
Countries (% of fund)
United Kingdom18.6%Switzerland16.7%Germany14.5%Netherlands10.4%France9.4%
Sectors (% of fund)
Financials32.4%Health Care17.6%Industrials12.4%Technology11.7%Consumer Discretionary8.6%

Listing venues

ESMA register (FIRDS) and official exchange lists
V3EL · Borsa Italiana (ETFplus), Euronext Amsterdam
V3DL · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
· Euronext Paris
+ 19 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · fund-docs.vanguard.com/ie000nrgx9m3_priipskid_en.pdf
Factsheet · fund-docs.vanguard.com/ESG_Developed_Europe_All_Cap_UCITS_ETF_EUR_Dist
Prospectus · fund-docs.vanguard.com/etf-prospectus-en.pdf
The live sheet, always up to date
rebalix.com/en/etf/IE000NRGX9M3
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · V3EL · IE000NRGX9M32